Elixirgen and Nippon Shinyaku sign EXG-7001 option agreement

June 26, 2026

Elixirgen Therapeutics Inc. has entered into an option agreement with Nippon Shinyaku Co. Ltd. for the development and commercialization of EXG-7001 for Duchenne muscular dystrophy. EXG-7001 is a locally administered, full-length dystrophin mRNA therapeutic that is currently in preclinical development for the treatment of Duchenne muscular dystrophy.

BioWorld Science Neurology/psychiatric

Today's news in brief

BioWorld

BioWorld briefs for July 20, 2026.

ALN-5288 lowers tau levels in preclinical models

BioWorld Science

Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....

LIT-002 is strong candidate for autism and neuropathic pain

BioWorld Science

Researchers from the University of Strasbourg and the Centre National de la Recherche Scientifique (CNRS) have presented data on LIT-002, a nonpeptide oxytocin...

News in brief

BioWorld Asia

BioWorld Asia briefs for July 21, 2026

Dorsal striatum and its neurons in Huntington's disease

Anle-138b reduces mHTT aggregation, improves pathological phenotypes in Huntington’s models

BioWorld Science

Anle-138b (emrusolmin) is a diphenylpyrazole compound that directly interacts with oligomeric species of disease-related aggregating proteins, reducing aggregate...